Amo Pharma Limited

With a US Food and Drug Administration partial clinical hold lifted, Avidity Biosciences, Inc. is moving forward with a Phase III trial of its antibody-oligonucleotide conjugate (AOC) candidate delp

Dyne Therapeutics has reported new data from Phase I/II studies in myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy that it believes can position each candidate for US accelerated appr

The US Food and Drug Administration is open to “innovative” statistical approaches to address challenges in rare disease drug development, FDA supervisory mathematical statistician Rebecca Chiu said a

The state of the financial markets for biopharmaceutical companies in 2024 is about as unpredictable as the weather in San Francisco during the annual J.P. Morgan Healthcare Conference. The forecast f